Significant reduction MACE with icosapent-ethyl in ASCVD and elevated triglycerides

MedNet.nl: Icosapent-ethyl lowers the number of major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease and elevated triglyceride levels in all quartiles of baseline cardiovascular disease risk. Patients with the highest residual risk benefit the most; the 5-year absolute risk reductions are greatest in them.